JP2023548632A5 - - Google Patents

Info

Publication number
JP2023548632A5
JP2023548632A5 JP2023535666A JP2023535666A JP2023548632A5 JP 2023548632 A5 JP2023548632 A5 JP 2023548632A5 JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023548632 A5 JP2023548632 A5 JP 2023548632A5
Authority
JP
Japan
Application number
JP2023535666A
Other languages
Japanese (ja)
Other versions
JP2023548632A (ja
JPWO2022093736A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056539 external-priority patent/WO2022093736A1/en
Publication of JP2023548632A publication Critical patent/JP2023548632A/ja
Publication of JPWO2022093736A5 publication Critical patent/JPWO2022093736A5/ja
Publication of JP2023548632A5 publication Critical patent/JP2023548632A5/ja
Pending legal-status Critical Current

Links

JP2023535666A 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法 Pending JP2023548632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105,472 2020-10-26
PCT/US2021/056539 WO2022093736A1 (en) 2020-10-26 2021-10-26 Compositions and methods for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2023548632A JP2023548632A (ja) 2023-11-17
JPWO2022093736A5 JPWO2022093736A5 (https=) 2024-10-30
JP2023548632A5 true JP2023548632A5 (https=) 2024-10-30

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535666A Pending JP2023548632A (ja) 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法

Country Status (8)

Country Link
US (1) US20240025954A1 (https=)
EP (1) EP4232462A1 (https=)
JP (1) JP2023548632A (https=)
CN (1) CN117098771A (https=)
AU (1) AU2021367952A1 (https=)
CA (1) CA3199433A1 (https=)
TW (1) TW202233655A (https=)
WO (1) WO2022093736A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア ファーマシューティカルズ インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
US12162929B2 (en) 2018-02-19 2024-12-10 New York University Alpha-synuclein single domain antibodies
GB201902392D0 (en) * 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
EP4132955A2 (en) * 2020-04-10 2023-02-15 SOLA Biosciences LLC Compositions and methods for the treatment of protein aggregation disorders
BR112022021604A2 (pt) * 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
JP2023548632A5 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)